Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 12/20 | 0.51 |
| ▸ | CASP2 | P42575 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | CASP6 | P55212 | 2/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408327 | 0.89 | KDM4E (0.49) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL10883505 | 0.80 | MAOA (0.48) | PDK2ALDH1A1HPGDHSD17B10CYP2D6 | |
| SCHEMBL8194264 | 0.80 | KDM4E (0.42) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL1871243 | 0.79 | CES1 (0.56) | CASP3GSK3BPDK2KDM4EDAO | |
| Vinyl Chloride SCHEMBL28309108 | 0.78 | KDM4E (0.41) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL9980565 | 0.77 | KDM4E (0.43) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL22525286 | 0.77 | DAO (0.58) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL1892075 | 0.76 | KDM4E (0.45) | CASP3CASP2CASP7CASP6CASP8 | |
| SCHEMBL28045932 | 0.76 | GABRA1 (0.43) | GSK3BPDK2PARP1DAOCYP2D6 | |
| SCHEMBL18983060 | 0.76 | MAPT (0.46) | PDK2ALDH1A1HPGDHSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CASP3 4069/4885CASP2 873/4885CASP7 3628/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CASP3 4064/4885CASP2 3809/4885CASP7 3993/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CASP3 816/4885CASP2 406/4885CASP7 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.